AstraZeneca (NYSE:AZN) was upgraded by equities research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a report released on Monday.
Several other research firms have also weighed in on AZN. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. BMO Capital Markets set a $38.00 price target on AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday, January 10th. Sanford C. Bernstein boosted their price target on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. Leerink Swann reaffirmed a “market perform” rating and set a $36.00 price target (up previously from $33.00) on shares of AstraZeneca in a research report on Thursday, January 18th. Finally, Jefferies Group raised AstraZeneca from a “hold” rating to a “buy” rating and boosted their price target for the stock from $28.43 to $36.70 in a research report on Monday. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. AstraZeneca has an average rating of “Hold” and a consensus price target of $36.32.
AstraZeneca stock opened at $34.77 on Monday. The firm has a market capitalization of $87,612.88, a P/E ratio of 14.67, a price-to-earnings-growth ratio of 2.06 and a beta of 0.71. AstraZeneca has a 1 year low of $28.43 and a 1 year high of $36.70. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.62 and a current ratio of 0.80.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings results on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.86. The firm had revenue of $5.78 billion for the quarter, compared to analyst estimates of $5.49 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The business’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.21 EPS. sell-side analysts forecast that AstraZeneca will post 1.69 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of AZN. Pinnacle Wealth Planning Services Inc. bought a new position in shares of AstraZeneca during the 4th quarter worth approximately $101,000. Valeo Financial Advisors LLC bought a new position in shares of AstraZeneca during the 3rd quarter worth approximately $133,000. Delpha Capital Management LLC bought a new position in shares of AstraZeneca during the 4th quarter worth approximately $152,000. Calton & Associates Inc. bought a new position in shares of AstraZeneca during the 4th quarter worth approximately $181,000. Finally, Wealthcare Advisory Partners LLC bought a new position in shares of AstraZeneca during the 3rd quarter worth approximately $184,000. Institutional investors own 15.13% of the company’s stock.
WARNING: “AstraZeneca (AZN) Upgraded to Strong-Buy by ValuEngine” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thestockobserver.com/2018/03/21/astrazeneca-azn-upgraded-to-strong-buy-by-valuengine.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.